Haemonetics Corporation $HAE Stock Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lowered its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 18.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,482 shares of the medical instruments supplier’s stock after selling 60,593 shares during the period. William Blair Investment Management LLC’s holdings in Haemonetics were worth $28,587,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of HAE. Brighton Jones LLC bought a new position in shares of Haemonetics during the 3rd quarter worth about $264,000. May Hill Capital LLC increased its stake in Haemonetics by 12.1% in the third quarter. May Hill Capital LLC now owns 25,093 shares of the medical instruments supplier’s stock valued at $2,642,000 after acquiring an additional 2,705 shares during the period. Vise Technologies Inc. bought a new stake in Haemonetics in the third quarter valued at about $613,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in Haemonetics by 178.6% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 11,700 shares of the medical instruments supplier’s stock worth $1,232,000 after purchasing an additional 7,500 shares in the last quarter. Finally, VestGen Advisors LLC acquired a new position in Haemonetics in the third quarter worth about $2,901,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Mizuho set a $165.00 price target on shares of Haemonetics in a research note on Thursday, November 5th. Barrington Research upped their price objective on Haemonetics from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Raymond James Financial increased their target price on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, September 3rd. Wall Street Zen downgraded Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Finally, Robert W. Baird boosted their price target on Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $129.00.

Insider Activity

In other news, CAO Farris Maryanne Maunsell sold 836 shares of Haemonetics stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total value of $101,147.64. Following the completion of the transaction, the chief accounting officer owned 5,828 shares in the company, valued at approximately $705,129.72. The trade was a 12.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.07% of the company’s stock.

Haemonetics Price Performance

HAE stock traded up $0.45 during trading on Friday, hitting $123.16. 439,677 shares of the stock traded hands, compared to its average volume of 686,811. Haemonetics Corporation has a one year low of $51.00 and a one year high of $132.00. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 55.23, a P/E/G ratio of 2.45 and a beta of 0.63. The company has a 50 day simple moving average of $113.34 and a 200 day simple moving average of $81.36. The company has a current ratio of 2.84, a quick ratio of 1.83 and a debt-to-equity ratio of 1.24.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. The firm had revenue of $357.76 million for the quarter, compared to analysts’ expectations of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.27 earnings per share. Equities analysts expect that Haemonetics Corporation will post 5.32 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.